Clinical Trial Update: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating NM26-2198 in healthy subjects and patients with moderate-to-severe Atopic Dermatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• NM26-2198

Snippet

Sponsor: Yellow Jersey Therapeutics AG | Conditions: Atopic Dermatitis | Phase 1 | Status: TERMINATED